



## ERYTECH to Present at Cowen & Company 39th Annual Healthcare Conference Meeting

Mar 08, 2019 | Press Releases

LYON, France and CAMBRIDGE, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- **ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that Gil Beyen, the company's chairman and chief executive officer, will present at the Cowen & Company 39<sup>th</sup> Annual Healthcare Conference on Wednesday, March 13, 2019 at The Marriott Copley Place, in Boston, MA.**

### Conference Details:

- Conference: Cowen and Company 39<sup>th</sup> Annual Health Care Conference
- Date: March 13, 2019
- Presentation Time: 8:40am EDT / 13:40 CET

### About ERYTECH: [www.erytech.com](http://www.erytech.com)

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates to address markets with high unmet medical needs.

ERYTECH's primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company's lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell's altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in preparations to enter Phase 2 clinical development for the treatment of triple-negative breast cancer. ERYTECH's next product candidate erymethionase, which consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers, has demonstrated promising preclinical results and is in preparations to enter Phase 1 clinical development.

ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme therapies (ERYZYME).

ERYTECH produces product candidates at its GMP-approved manufacturing site in Lyon, France, and at the American Red Cross in Philadelphia, USA. A large-scale GMP manufacturing facility is under construction in New Jersey, USA.

*ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.*

### CONTACTS

ERYTECH   
Eric Soyer  
CFO & COO

+33 4 78 74 44 38

[investors@erytech.com](mailto:investors@erytech.com)NewCapMathilde Bohin / Louis-Victor Delouvrier

Investor relations

Nicolas Merigeau

Media relations

+33 1 44 71 94 94

[erytech@newcap.eu](mailto:erytech@newcap.eu)



Source: Erytech Pharma S.A.